관련링크
본문
SUMMIT, N.J.--( / ) October 30, 2017 -- Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III RADIANCE™ Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, versus a first-line treatment, Avonex® (interferon beta-1a) (IFN), in patients with relapsing multiple sclerosis (RMS). The results were presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting, which was held in Paris, October 25-28, 2017.
“As physicians, we recognize the increased need for additional effective and safe therapeutic options for use earlier in the treatment of RMS,” said Bruce Cree, M.D., Ph.D., M.A.S., Associate Professor of Clinical Neurology at the University of California San Francisco Weill Institute for Neurosciences and an author of the abstract. “Based on these data, ozanimod has the potential to provide RMS patients and their physicians a novel oral option for treating this debilitating illness.”
The RADIANCE Part B study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod compared with IFN in 1,320 patients with RMS in 21 countries treated for two years. A significant reduction in annualized relapse rate (ARR) was demonstrated for ozanimod 1 mg (ARR=0.17, p<0.0001) and for ozanimod 0.5 mg (ARR=0.22, p=0.0167) compared with IFN (ARR=0.28) over two years of treatment.
A significant reduction in new or enlarging T2 lesions was demonstrated for ozanimod 1 mg (42 percent, p<0.0001) and 0.5 mg (34 percent, p=0.0001) compared with IFN. A significant reduction in gadolinium-enhanced MRI lesions was also demonstrated for ozanimod 1 mg (53 percent, p=0.0006) and ozanimod 0.5 mg (47 percent, p=0.0030) compared with IFN.
In RADIANCE Part B, a reduction in brain volume loss, a measure associated with MS disease progression, was observed for both ozanimod doses compared with IFN. Whole brain volume loss was reduced by 27 percent with the 1 mg dose of ozanimod (median percent change from baseline to 2 years: -0.69, nominally significant p<0.0001) and by 25 percent in the 0.5 mg group (-0.71, nominally significant p <0.0001) versus IFN (-0.94) at two years.
In a pre-specified pooled analysis of the SUNBEAM™ and RADIANCE Part B studies, ozanimod did not reach statistical significance compared with IFN in the time to 3-month confirmed disability progression. A very low rate of disability progression was observed across all treatment groups. Of the 2,659 patients assessed, the number of patients with 3-month confirmed disability progression by the end of the study was 67 (7.6 percent) patients in the ozanimod 1 mg group and 58 (6.5 percent) in the ozanimod 0.5 mg group compared with 69 (7.8 percent) in the IFN group. In RADIANCE Part B, the number of patients with 3-month confirmed disability progression by the end of the study was 54 (12.5 percent) in the ozanimod 1 mg group and 41 (9.3 percent) in the ozanimod 0.5 mg group compared with 50 (11.3 percent) in the IFN group.
Treatment-emergent adverse events (AEs) were experienced by 75 percent of patients on ozanimod 1 mg, 74 percent on ozanimod 0.5 mg and 83 percent on IFN. Most AEs were mild; the most common AEs across all treatment groups were nasopharyngitis, headache, alanine aminotransferase increased, influenza-like illness, hypertension, gamma-glutamyl transferase increased, pharyngitis and urinary tract infection. AEs of alanine aminotransferase increased were low, transient and generally resolved without study drug discontinuation. The overall incidences of serious AEs were low and similar across treatment arms (ozanimod 1 mg, 6.5 percent; 0.5 mg, 7.1 percent; IFN, 6.4 percent). The percentages of patients who discontinued study drug due to AEs were 3.0 percent for ozanimod 1 mg, 3.2 percent for ozanimod 0.5 mg and 4.1 percent for IFN.
No second degree or higher atrioventricular blocks were observed. Serious cardiac AEs were 0.0 percent for ozanimod 1 mg, 0.7 percent for ozanimod 0.5 mg and 0.5 percent for IFN. Infection rates were similar across treatment arms; serious infection rates were low and similar across treatment arms, with no serious opportunistic infections.
The overall safety and tolerability profile was consistent with results from the previously reported phase II RADIANCE Part A and phase III SUNBEAM studies in RMS.
“Given the totality of the data for ozanimod, we believe that the benefit-risk profile supports pursuing ozanimod as a potential new oral therapeutic option and look forward to filing regulatory submissions in the U.S. by the end of 2017 and in the EU in the first half of 2018,” said Terrie Curran, President, Celgene Inflammation and Immunology.
Celgene will host a live webcast from the MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting today at 12 p.m. EDT (6 p.m. CEST). Members of Celgene‘s management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The webcast will be available in the Investor Relations section of the Company’s website at
About RADIANCE™
RADIANCE Part B is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 24-month treatment period. The study included 1,320 people living with RMS across 147 sites in 21 countries.
The primary endpoint of the trial was ARR over 24 months. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months, number of gadolinium-enhanced brain MRI lesions at month 24 and percent change from baseline in brain volume at month 24.
An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.
About SUNBEAM™
SUNBEAM is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 12-month treatment period. The study included 1,346 people living with RMS across 152 sites in 20 countries.
The primary endpoint of the trial was ARR during the treatment period. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 12 months, number of gadolinium-enhanced brain MRI lesions at month 12 and percent change from baseline in brain volume at month 12.
An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.
About Ozanimod
Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, ulcerative colitis and Crohn's disease. Selective binding with S1PR1 is believed to inhibit a specific sub set of activated lymphocytes from migrating to sites of inflammation. The result is a reduction of circulating T and B lymphocytes that leads to anti-inflammatory activity. Importantly, immune surveillance is maintained.
Selective binding with S1PR5 is thought to activate specific cells within the CNS. This has the potential to enhance remyelination and prevent synaptic defects. Ultimately, neurological damage may be prevented.
Ozanimod is an investigational compound that is not approved for any use in any country.
About Multiple Sclerosis
Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate ? a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. Multiple sclerosis affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.
Relapsing multiple sclerosis (RMS) is characterized by clearly defined attacks of worsening neurologic function. These attacks ? often called relapses, flare-ups or exacerbations ? are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with progressive forms of the disease.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next?generation solutions in protein homeostasis, immuno?oncology, epigenetics, immunology and neuro?inflammation. For more information, please visit Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
TEMPE, ARIZ.--( / ) November 21, 2017 -- Consumers worldwide are spending 야한짓 카사노바 more time online and are quick to avoid websites that 스카이레몬 글로리티비 provide poor user experiences or have had security breaches, according to the latest “State of the User Experience” wguTN TEMPE,report from Limelight Networks, (Nasdaq:LLNW), a global leader in digital content delivery. The annual global report, which highlights consumer online behaviors and expectations, 스카이레몬 경인 found major increases in 스카이레몬 이유 time spent online and the impact of online experiences on customer loyalty. 야한짓 하늘하늘
Globally, 스카이레몬 강혜지 남방동고스톱 Globally,than 45 percent of people spend at least 15 hours a week online 스카이레몬 황다혜 outside of work - a 64 percent increase 야한짓 이서영 from last year. Smartphones are the primary device used to access online content, and 오산동풀팟홀덤 Globally,than half (56 스카이레몬 xxmiso percent) of worldwide consumers expect fast 야한짓 이유이 web performance regardless of what device 머니상 Globally,are using.
Poor experiences frequently lead to lost sales. Nearly half (49 percent) of global 토렌트집 Poor한국비트코인거래소 Poorsaid they will not 스카이레몬 hellokind wait more than 5 seconds for 야한짓 a web page to load, and 43 percent would move to a different site to make a purchase if a website was too slow. More than 12 percent of consumers 야한짓 앙기모띠넷 surveyed will 스카이레몬 야동사이트 not re-visit a website 야한짓 오피걸스야동 after previously experiencing slow performance - double the 스카이레몬 반서진 number from last year’s survey.
Consumers also want to know their information is being safeguarded online. More than 스카이레몬 이지유 75 percent have a negative opinion of a brand after it has experienced a security breach, 야한짓 mistymacallister and 40 percent say they will 스카이레몬 별킹 야한짓 별킹 몬부란 Consumersshop at a website 야한짓 캠스 that has been the victim of a cyber-attack. 스카이레몬 미지
“In today’s crowded market, brands can’t risk delivering a poor online experience 스카이레몬 나타샤 to their 스카이레몬 김이브님 customers,” said Michael Milligan, Senior Director at Limelight Networks. “Security 188BET “In나이트팔라스게임 “Inperformance and other elements of an 야한짓 지유님 inefficient online experience impact a shopper’s actions and have long-lasting effects on brand reputation and 야한짓 customer retention.”
Additional 색스동영상 Additional야한만화보기 Additional스카이레몬 타미미 the 스카이레몬 텀블러야동 report 야한짓 show: 야한짓 화정님
· Good experiences go a long way. The top factors in 섹수 ·to purchase a product from a website are the 스카이레몬 근친/기타고백썰 야한짓 근친/기타고백썰 “ability to easily search and find items” and “fast online performance.” After 야한짓 a positive experience on a website, 75 percent of worldwide consumers surveyed will recommend that brand to 움짤저장소 ·friend. Consumers in India and the Philippines are the most likely to do so, with 95 percent willing to recommend 스카이레몬 캣툰 a 리플티비 ·based on a good experience.
· Social media wins the popularity contest. Social media is the top choice for time spent online by global 야한짓 consumers, 스카이레몬 섹툰 at an 리플티비 ·of four hours 14 minutes per week. People 18-35 spend more 야한짓 time watching online video than any other activity, while those older than 60 야한짓 UKSS prefer spending time reading online news.
· Smartphones are 야한짓 preferred by younger consumers. 스카이레몬 오마이툰 Globally, smartphones are the primary device used for online activities. 야한짓 Smartphones are the 리플티비 ·device for accessing 스카이레몬 꿀넷 online content by 맨토 ·and people 45 and younger. Men and people older than 45 prefer 야한짓 laptop 스카이레몬 computers.
· 미유키아리스 ·야한짓 구멍가게 are spending more time online. 포커고수 ·in the U.S. and the U.K. spend the most time online, with more than half in each country spending more than 15 hours a week 리희 ·Globally, 스카이레몬 와이고수 people 46-60 spend the most time online, with 49 percent online for 스카이레몬 꽁툰 more than 15 hours a week. For comparison, 41 percent of young millennials (ages 18-25) spend more than 15 hours online each week.
The “State of the User Experience” report is based on 단타 The단타 Theof 3,500 respondents in 단타 TheIndia, Japan, 스카이레몬 토마토커뮤니티솔루션 South Korea, 야한짓 먹튀신고/검증사이트 Philippines, the U.K., and 야한짓 EGGC the 야한짓 먹튀킬러 U.S. The full report 스카이레몬 오메가카지노 is available here ().
짱공유 About스카이레몬 Limelight 스카이레몬 슈어코리아 야한짓 슈어코리아
Limelight Networks Inc., (NASDAQ: LLNW), a global leader in digital content delivery, empowers customers to better engage online audiences by enabling them to securely manage and globally deliver digital content, on any device. The company’s 야한짓 영앤리치 Limelight Orchestrate Platform includes a global 야한짓 나쁜토끼영상관 infrastructure with a fully-integrated 해외라이브스코어 Limelightof capabilities and services to help you address all your content 스카이레몬 라인툰 delivery needs. The Orchestrate 여우알바 Limelightsolves your most 야한짓 소나기티비공. important content delivery challenges so you can 스카이레몬 토토북 deliver the next great digital experience anywhere. For more information, visit , follow us on Twitter, Facebook, 여우알바 LimelightLinkedIn.
View 야한짓 마나모아구 source 로또공략법 Viewon 스카이레몬 SUKEBEI해외 businesswire.com:Korea Newswire distributes your news across 야한짓 토다와 every media 스카이레몬 스포츠중계비비TV channels 스카이레몬 through the industry’s largest press release distribution network
 전화번호 : |
 영업시간 : |
 홈페이지 : |
 위치정보 : |
댓글목록
등록된 댓글이 없습니다.
